Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictors of Unfavourable Outcomes in Alteplase-Treated Stroke
NCT06058884Phase 4Completed
- Sponsor
- Kafrelsheikh University
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of tissue-plasminogen activator in ischemic stroke (2 arms), sponsored by Kafrelsheikh University. Primary endpoints: modified Rankin Scale at 90 days and Predictors of the unfavourable outcomes at 90 days. Started Jan 2022; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06058884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058884.